Case series analysis: association between new antidepressant exposure episode and first MI
| Drug exposure period | No of cases | No of first MIs | IRR (95% CI) |
|---|---|---|---|
| *After first prescription; †29 days after first prescription to 28 days after last prescription; ‡29–56 days after last prescription. | |||
| IRR, incidence rate ratio. | |||
| SSRIs | 4132 | ||
| Any SSRI | |||
| Day of first prescription | 13 | 4.76 (2.76 to 8.18) | |
| 1–7 days* | 37 | 1.94 (1.40 to 2.68) | |
| 8–14 days* | 25 | 1.31 (0.89 to 1.95) | |
| 15–21 days* | 24 | 1.27 (0.85 to 1.90) | |
| 22–28 days* | 22 | 1.18 (0.77 to 1.79) | |
| Remaining exposure† | 284 | 0.96 (0.83 to 1.12) | |
| Withdrawal period‡ | 119 | 1.82 (1.51 to 2.19) | |
| Unexposed period | 3608 | 1.00 | |
| Fluoxetine | 2121 | ||
| Day of first prescription | 10 | 7.23 (3.88 to 13.46) | |
| 1–7 days* | 16 | 1.66 (1.01 to 2.71) | |
| 8–14 days* | 14 | 1.46 (0.86 to 2.47) | |
| 15–21 days* | 12 | 1.25 (0.71 to 2.21) | |
| 22–28 days* | 12 | 1.26 (0.71 to 2.23) | |
| Remaining exposure† | 125 | 0.96 (0.77 to 1.20) | |
| Withdrawal period‡ | 63 | 1.84 (1.43 to 2.37) | |
| Unexposed period | 1869 | 1.00 | |
| Paroxetine | 1619 | ||
| Day of first prescription | 3 | 3.04 (0.98 to 9.43) | |
| 1–7 days* | 18 | 2.61 (1.64 to 4.17) | |
| 8–14 days* | 11 | 1.61 (0.89 to 2.91) | |
| 15–21 days* | 11 | 1.62 (0.89 to 2.94) | |
| 22–28 days* | 11 | 1.64 (0.91 to 2.98) | |
| Remaining exposure† | 98 | 0.94 (0.73 to 1.21) | |
| Withdrawal period‡ | 46 | 1.94 (1.44 to 2.62) | |
| Unexposed period | 1421 | 1.00 | |
| TCAs | |||
| Any TCA | 6735 | ||
| Day of first prescription | 9 | 1.81 (0.94 to 3.47) | |
| 1–7 days* | 50 | 1.44 (1.09 to 1.90) | |
| 8–14 days* | 49 | 1.41 (1.07 to 1.87) | |
| 15–21 days* | 62 | 1.80 (1.40 to 2.31) | |
| 22–28 days* | 48 | 1.40 (1.05 to 1.86) | |
| Remaining exposure† | 805 | 0.96 (0.86 to 1.09) | |
| Withdrawal period‡ | 284 | 2.32 (2.05 to 2.62) | |
| Unexposed period | 5428 | 1.00 | |
| Dothiepin | 2848 | ||
| Day of first prescription | 4 | 2.00 (0.75 to 5.32) | |
| 1–7 days* | 20 | 1.43 (0.92 to 2.22) | |
| 8–14 days* | 21 | 1.50 (0.98 to 2.31) | |
| 15–21 days* | 22 | 1.58 (1.04 to 2.41) | |
| 22–28 days* | 16 | 1.16 (0.71 to 1.89) | |
| Remaining exposure† | 274 | 0.83 (0.69 to 1.00) | |
| Withdrawal period‡ | 108 | 2.15 (1.76 to 2.61) | |
| Unexposed period | 2383 | 1.00 | |
| Amitriptyline | 2928 | ||
| Day of first prescription | 0 | ||
| 1–7 days* | 25 | 1.85 (1.24 to 2.75) | |
| 8–14 days* | 22 | 1.63 (1.07 to 2.49) | |
| 15–21 days* | 23 | 1.71 (1.14 to 2.59) | |
| 22–28 days* | 14 | 1.05 (0.62 to 1.78) | |
| Remaining exposure† | 270 | 1.05 (0.86 to 1.27) | |
| Withdrawal period‡ | 105 | 2.21 (1.81 to 2.69) | |
| Unexposed period | 2469 | 1.00 | |
| Lofepramine | 1628 | ||
| Day of first prescription | 6 | 5.35 (2.40 to 11.91) | |
| 1–7 days* | 12 | 1.53 (0.87 to 2.71) | |
| 8–14 days* | 12 | 1.55 (0.87 to 2.73) | |
| 15–21 days* | 19 | 2.47 (1.56 to 3.88) | |
| 22–28 days* | 14 | 1.84 (1.08 to 3.12) | |
| Remaining exposure† | 109 | 1.14 (0.87 to 1.49) | |
| Withdrawal period‡ | 48 | 1.71 (1.28 to 2.29) | |
| Unexposed period | 1408 | 1.00 | |